keyword
https://read.qxmd.com/read/38307188/botulinum-toxin-type-a-blocks-aquaporin-5-trafficking-by-decreasing-synaptosomal-associated-protein-23-in-submandibular-acinar-cells
#21
JOURNAL ARTICLE
Hui Xu, Huabing Ge, Zhigang Cai
The trafficking of aquaporin 5 (AQP5) is critical for salivary secretion. Synaptosomal-associated protein 23 (SNAP23) is an important regulator in the process of membrane fusion. However, the role of SNAP23 on AQP5 trafficking has not been explored. Botulinum toxin type A (BoNT/A) is a bacterial toxin that effectively treats sialorrhea. We previously reported that BoNT/A induced AQP5 redistribution in cultured acinar cells, but the mechanism remained unclear. In this study, SNAP23 was predominantly localized to the plasma membrane of acinar cells in the rat submandibular gland (SMG) and colocalized with AQP5 at the apical membrane of acinar cells...
January 31, 2024: Experimental Cell Research
https://read.qxmd.com/read/38294288/onabotulinum-toxin-a-bont-a-for-drooling-in-children-a-systematic-review-and-meta-analysis
#22
REVIEW
Haresh Oad, Alix Maltezeanu, Sabrina D da Silva, Sam J Daniel
INTRODUCTION: Sialorrhea, also known as drooling, hypersalivation, or ptyalism, has a significant impact on the medical and psychosocial well-being of children. Onabotulinum toxin A (BoNT-A) is the most commonly used botulinum toxin worldwide for the treatment of sialorrhea in children. OBJECTIVES: To conduct a comprehensive systematic review and meta-analysis to assess the clinical efficacy and potential adverse effects of BoNT-A as a treatment for drooling in children...
January 31, 2024: Laryngoscope
https://read.qxmd.com/read/38294269/the-usefulness-of-salivary-gland-organoids-for-evaluation-of-the-potency-of-botulinum-neurotoxin
#23
JOURNAL ARTICLE
Yeo-Jun Yoon, Jae-Yol Lim
BACKGROUND AND OBJECTIVES: Botulinum neurotoxin (BoNT) is a substance used to treat chronic sialorrhea, muscle dystonia, and is used in cosmetic applications. Measuring the potency of BoNT is crucial because it acts even with a small amount. However, the current methods for measuring the potency of BoNT involve using two-dimensional neuroblastoma cell line-based methods. In this study, we aimed to develop a new method to measure the potency of BoNT using a three-dimensional organoid culture system...
January 31, 2024: Laryngoscope
https://read.qxmd.com/read/38264389/a-palliative-care-approach-to-amyotrophic-lateral-sclerosis
#24
JOURNAL ARTICLE
Cláudio Gouveia, Licínia Araújo, Susete Freitas, João Correia, Vilma Passos, Graciela Camacho, Luísa Gomes, Helena Fragoeiro, Cristiana Camacho, Beatriz Chambino
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a degenerative disease characterized by motor dysfunction. Currently, treatment options are limited and management is based mostly on symptom control and quality of life optimization, so palliative care plays a fundamental role. Our objective was to characterize the ALS population in Madeira Island that was referenced and/or followed by a palliative care unit over a five-year period. METHODS: Longitudinal, retrospective, descriptive, and observational study to analyze patients with ALS who were referred and/or followed by a palliative care unit during a five-year period, between 2017 and 2021...
December 2023: Curēus
https://read.qxmd.com/read/38263629/sialorrhea-working-with-people-with-disability-for-better-outcomes
#25
JOURNAL ARTICLE
Dinah Susan Reddihough
No abstract text is available yet for this article.
January 23, 2024: Developmental Medicine and Child Neurology
https://read.qxmd.com/read/38241761/use-of-botox-for-sialorrhea-and-dysphagia-in-the-neonatal-population
#26
JOURNAL ARTICLE
Nathan Lu, Nadine Haykal, Jennifer L McCoy, Allison B J Tobey
INTRODUCTION: Botox is frequently used for sialorrhea in patients with compromised airways and those with etiologies causing difficulty with secretion management (i.e. strokes, neurologic disorders, etc.). There are no published studies regarding the use of botulinum toxin (BoNT) in the neonate population. We aim to discuss our experience and safety of BoNT use in the neonate population in regards to alleviating secretion management and airway protection. METHODS: Retrospective review of neonates admitted to the neonatal intensive care unit (NICU) ≤12 months of age who received BoNT injection to submandibular (SMG) and parotid (PG) glands for sialorrhea/dysphagia...
December 26, 2023: American Journal of Otolaryngology
https://read.qxmd.com/read/38228282/clinical-evaluation-of-the-sedative-antinociceptive-and-cardiorespiratory-effects-of-intranasal-dexmedetomidine-combined-with-methadone-in-healthy-dogs
#27
JOURNAL ARTICLE
R Bustamante, S Canfrán, I A Gómez de Segura
In this prospective, randomised, blinded clinical study, we compared the sedative, antinociceptive and cardiorespiratory effects of intranasal (IN) dexmedetomidine at 5 μg/kg (diluted with 0.03 mL/kg NaCl 0.9%, DEX) with or without methadone (0.3 mg/kg; DEXMET), through a mucosal atomization device to one nostril in twenty healthy client-owned dogs. At 5-min intervals over 45 min, sedation score, onset, cardiopulmonary variables, mechanical nociceptive thresholds (MNTs) were assessed, also ease of administration, adverse effects, and response to IV catheterization...
January 14, 2024: Veterinary Journal
https://read.qxmd.com/read/38186486/the-challenge-of-managing-refractory-psychosis-amid-multiple-medication-side-effects-a-case-report-and-review-of-the-literature
#28
Alejandro Rodulfo, Sabina Goldstein, Zina Meriden
Antipsychotics are the mainstay for the treatment of schizophrenia and other psychotic disorders; however, these agents are associated with an extensive side effect profile that may complicate treatment outcomes. We present the case of a 35-year-old woman with a history of schizoaffective disorder and five prior psychiatric hospitalizations. The patient first presented to the hospital for disorganized behavior, in addition to poor sleep, auditory hallucinations, and racing thoughts in the context of medication nonadherence...
December 2023: Curēus
https://read.qxmd.com/read/38131516/management-of-neurological-problems-in-children-on-home-invasive-mechanical-ventilation
#29
JOURNAL ARTICLE
Yavuz Sayar, Miraç Yıldırım, Serap Teber
INTRODUCTION: Home invasive mechanical ventilation (HIMV) has become a crucial long-term respiratory support for children with neurological disorders, but requires advanced technological skills and 24-h care. The increasing global population of children on HIMV is attributed to advancements in intensive care and improved survival rates. METHOD: The manuscript will review the most common neurological problems encountered in children on HIMV. CONCLUSION: The manuscript emphasizes the multidisciplinary nature of managing these patients, involving pediatric pulmonologists, pediatric neurologists, pediatric intensivists, nurses, therapists, dietitians, psychologists, and caregivers...
December 22, 2023: Pediatric Pulmonology
https://read.qxmd.com/read/38130339/ophthalmic-atropine-a-typical-anticholinergic-toxidrome-from-an-atypical-old-culprit
#30
JOURNAL ARTICLE
Michael Raschka, Marshal Khant
Included on the World Health Organization Model Lists of Essential Medicines, atropine remains a cornerstone medication that is used for a myriad of clinical indications. Systemically, atropine carries indications for the treatment of asymptomatic and symptomatic bradycardia, reduction of salivation and bronchial secretions prior to surgery, and as an antidote for a variety of poisoning agents (i.e., carbamate or organophosphate insecticides, nerve agents, muscarine-containing mushrooms). Topically, atropine is administered via the ophthalmic route for the treatment of cycloplegia, mydriasis, and amblyopia or may be administered sublingually to treat chronic sialorrhea...
2023: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://read.qxmd.com/read/38130251/the-effectiveness-of-ultrasound-guided-injection-of-btx-a-in-the-management-of-sialorrhea-in-neurogenic-dysphagia-patients
#31
JOURNAL ARTICLE
Zitong He, Suling Chen, Peishan Zeng, Meng Dai, Xiaomei Wei, Jiemei Chen, Xue Zhang, Zulin Dou, Hongmei Wen, Chao Li
OBJECTIVE: To evaluate the effectiveness of ultrasound-guided injection of botulinum toxin type A (BTX-A) in treating sialorrhea. METHODS: We recruited 32 sialorrhea subjects and they received an ultrasound-guided injection of BTX-A. The extent of salivation was evaluated according to the Visual Analog Scale (VAS), Drooling Severity and Frequency Scale (DSFS), and Saliva Flow Rate (SFR). Laryngeal secretions were evaluated based on Fiberoptic Endoscopic Evaluation of Swallowing (FEES) rated according to the Murray Secretion Scale (MSS)...
December 2023: Laryngoscope Investigative Otolaryngology
https://read.qxmd.com/read/38100776/evaluation-and-comparison-of-the-effectiveness-of-atropine-eye-drops-ipratropium-bromide-nasal-spray-and-amitriptyline-tablet-in-the-management-of-clozapine-associated-sialorrhea-in-patients-with-refractory-schizophrenia-a-randomized-clinical-trial
#32
RANDOMIZED CONTROLLED TRIAL
Fatemeh Mohammad-Gholizad, Iman Karimzadeh, Ebrahim Moghimi-Sarani, Mahdi Arshadi, Negar Mortazavi
PURPOSE: Clozapine, a second-generation antipsychotic medication, is mainly indicated for managing treatment-resistant schizophrenia. Among all the nonthreatening adverse effects of clozapine, sialorrhea is a stigmatizing complication occurring in approximately 31.0% to 97.4% of patients. In this study, 2 topical agents (atropine eye drop and ipratropium nasal spray) and a systemic medication (amitriptyline) were compared simultaneously for the management of clozapine-associated sialorrhea...
January 2024: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/38058756/expanding-phenotype-of-syt1-related-neurodevelopmental-disorder-case-report-and-literature-review
#33
JOURNAL ARTICLE
Carlo Alberto Cesaroni, Carlotta Spagnoli, Margherita Baga, Susanna Rizzi, Daniele Frattini, Stefano Giuseppe Caraffi, Marzia Pollazzon, Livia Garavelli, Carlo Fusco
INTRODUCTION: Synaptotagmin 1 (SYT1), the predominant SYT isoform in the central nervous system, likely acts by promoting vesicle docking, deforming the plasma membrane via Ca2+ -dependent membrane penetration. CASE PRESENTATION: Here, we describe a 21-year-old woman harboring a novel variant in the SYT1 gene, who presents with a complex phenotype, featuring severe intellectual disability, absent speech, behavioral abnormalities, motor stereotypies, dystonic posturing of her hands, a hyperkinetic movement disorder in her childhood, infantile hypotonia, sialorrhea, mild dysmorphic features, epilepsy, peculiar EEG findings, and severe scoliosis...
December 2023: Molecular Syndromology
https://read.qxmd.com/read/38056063/botulinum-toxin-treatment-in-parkinsonism
#34
REVIEW
Charenya Anandan, Joseph Jankovic
Botulinum toxin (BoNT) was approved by the United States Food and Drug Administration (FDA) in 1989 for facial movement disorders and strabismus, but since that time its indications have been expanding beyond neurologic and ophthalmologic disorders. This article is a narrative review of the therapeutic use of BoNT in tremors, dystonia, sialorrhea, bladder and other autonomic symptoms, levodopa-induced dyskinesia and other problems occuring in the setting of parkinsonism. Though FDA approval is lacking for some of these indications, expert experiences have shown that BoNT is often beneficial in this group of patients...
January 15, 2024: Journal of the Neurological Sciences
https://read.qxmd.com/read/38044765/orofacial-uses-of-botox-in-dentistry-and-their-associated-risks-a-population-based-cross-sectional-study-in-saudi-arabia
#35
JOURNAL ARTICLE
A K Demyati, A A Nassar
BACKGROUND: Various healthcare professionals, including dentists, provide botulinum toxin (Botox) for cosmetic and therapeutic treatment. In dentistry, it has multiple uses, such as gummy smile, bruxism, sialorrhea, muscle spasm, and orofacial pain, yet unwanted side effects may arise. AIMS: This study aimed to investigate the participants' perspective regarding the scope of Botox in dentistry and its associated risk, provider involvement, and factors affecting the choice of which healthcare professions administer Botox injections in Saudi Arabia...
November 1, 2023: Nigerian Journal of Clinical Practice
https://read.qxmd.com/read/38044099/application-site-of-transdermal-scopolamine-influences-efficacy-and-drug-concentration-in-salivary-glands-in-rats
#36
JOURNAL ARTICLE
Natsuko Ishida, Yoshitaka Oshima, Ayano Katsura, Rikako Imamura, Hiroshi Arakawa, Tsutomu Shimada, Satoshi Mizuno, Yoshimichi Sai, Yukio Suga, Ryo Matsushita
Transdermal scopolamine applied to the postauricular area is used to treat drooling. We investigated the duration of action of scopolamine ointment and the effect of the application site on drug efficacy and concentration in the salivary glands of rats. Scopolamine ointment was applied to the skin over the salivary glands (SSG) and back (SB). Saliva volume was measured after intraperitoneal administration of pilocarpine. Blood and salivary glands were collected after scopolamine ointment application, and scopolamine concentrations in the plasma and salivary glands were measured...
2023: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38043299/comparing-botulinum-toxin-and-4-duct-ligation-for-sialorrhea-in-children-a-systematic-review
#37
JOURNAL ARTICLE
Tu-Anh N Ha, Michael C Shih, Elton M Lambert
INTRODUCTION: Sialorrhea or drooling can result in physical and psychosocial complications, such as aspiration and social isolation. Treatment options include botulinum toxin into the salivary glands and 4-duct ligation (i.e., simultaneous ligation of the bilateral parotid and submandibular ducts). This systematic review aimed to compare the efficacy and complication rates of botulinum toxin and 4-duct ligation for the treatment of drooling in children. METHODS: Following PRISMA guidelines, PubMed, Embase, Web of Science, and Cochrane Library were searched from inception through June 17, 2021 for studies examining the efficacy of botulinum toxin or 4-duct ligation for drooling in children...
November 24, 2023: American Journal of Otolaryngology
https://read.qxmd.com/read/38021341/recommendations-for-a-paradigm-shift-in-approach-to-increase-the-recognition-and-treatment-of-sialorrhea-in-parkinson-s-disease
#38
REVIEW
Bruno Bergmans, Veronica Clark, Stuart H Isaacson, Tobias Bäumer
Sialorrhea, or drooling, is defined as excessive saliva accumulation and unwanted loss of saliva from the mouth or over the tongue and into the pharynx. It constitutes one of the most frequent and bothersome complaints of patients with Parkinson's disease (PD), affecting up to 84% of them. Sialorrhea is a distressing and challenging condition that may result in social isolation, embarrassment, depression, skin infections, poor oral health, and aspiration pneumonia. To better understand the burden of sialorrhea on patients with PD, Parkinson's Europe carried out a worldwide patient survey which showed that sialorrhea remains an underrecognized and undertreated issue in patients with PD...
2023: Clinical parkinsonism & related disorders
https://read.qxmd.com/read/38008865/pulmonary-and-clinical-outcomes-after-bilateral-submandibular-gland-excision-and-parotid-duct-ligation-for-refractory-sialorrhea
#39
JOURNAL ARTICLE
Ashley L Miller, Erik B Hysinger, Meredith E Tabangin, Cherie Torres-Silva, Alessandro de Alarcon, Catherine K Hart
IMPORTANCE: Refractory sialorrhea in children can result in pulmonary aspiration and irreversible lung damage. Despite many studies devoted to the surgical treatment of sialorrhea, there is a paucity of objective outcome measures after surgery, especially with regard to pulmonary health. OBJECTIVES: To assess whether bilateral submandibular gland excision and bilateral parotid duct ligation ("DROOL" procedure) is associated with reduced pulmonary inflammation in bronchoalveolar lavage (BAL) samples after surgery and to assess patient factors associated with improvement after surgery...
January 1, 2024: JAMA Otolaryngology—Head & Neck Surgery
https://read.qxmd.com/read/37992139/medication-impact-on-oral-health-in-schizophrenia
#40
JOURNAL ARTICLE
L Urien, N Jauregizar, U Lertxundi, U Fernández, T Morera-Herreras
BACKGROUND: Patients with schizophrenia constitute a particularly vulnerable group for oral diseases. Among the different factors involved, we aimed to examine the evidence of how drugs could contribute to the poorer oral health of this population. MATERIAL AND METHODS: An overview of the potential impact of medication on dental/oral health among people with schizophrenia was proposed focusing on selected literature. RESULTS: Studies show a higher dental caries and degree of periodontal diseases in this population and point to drug-induced xerostomia as an important risk factor for oral health deterioration...
November 22, 2023: Medicina Oral, Patología Oral y Cirugía Bucal
keyword
keyword
6609
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.